Serum selenium measurements in women with early-stage breast cancer with and without chemotherapy-induced ovarian failure

被引:0
|
作者
Hollie A. Breedlove
Anne M. Smith
Raymond F. Burk
Kristina E. Hill
Charles L. Shapiro
机构
[1] The Ohio State University,Department of Human Nutrition
[2] Vanderbilt University School of Medicine,Division of Gastroenterology
[3] The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute,Division of Hematology and Oncology
[4] The Ohio State University,Department of Human Nutrition
[5] The Ohio State University,undefined
来源
Breast Cancer Research and Treatment | 2006年 / 97卷
关键词
breast cancer; chemotherapy; estrogen; glutathione peroxidase; ovarian failure; selenium; selenomethionine; selenoprotein P;
D O I
暂无
中图分类号
学科分类号
摘要
Blood selenium has been shown to decline as breast cancer progresses and fluctuate with estrogen. The objective of this study was to determine the effect of estrogen depletion resulting from chemotherapy-induced ovarian failure on serum selenium and selenoproteins in stage I/II premenopausal breast cancer patients. Serum selenium, glutathione peroxidase (GPx) activity, and selenoprotein P (SelP) were measured and a dietary questionnaire was completed at baseline (before chemotherapy) and 6, 12, and 24 months after start of chemotherapy. Twelve months after the start of adjuvant chemotherapy 33 (75%) patients developed ovarian failure (OF) and 11 (25%) retained menstrual function (non-OF). Dietary selenium intake was 30–58% above the Recommended Dietary Allowance for both groups. By six months the mean estradiol (pg/ml) was lower in the OF group than in the non-OF group (32±5 versus 140±62 pg/ml, p=0.01) and this difference was maintained at 12 and 24 months. However, there was no differences in serum selenium, GPx activity, or SelP in the OF and non-OF groups at 6, 12, and 24 months. Selenium status in premenopausal breast cancer patients, as measured by serum selenium, GPx and SelP, was within the normal range before and following adjuvant chemotherapy, and was not affected by chemotherapy-induced ovarian failure.
引用
收藏
页码:225 / 230
页数:5
相关论文
共 50 条
  • [1] Serum selenium measurements in women with early-stage breast cancer with and without chemotherapy-induced ovarian failure
    Breedlove, Hollie A.
    Smith, Anne M.
    Burk, Raymond F.
    Hill, Kristina E.
    Shapiro, Charles L.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 97 (03) : 225 - 230
  • [2] Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer
    Han, Yunwei
    Yu, Zhihao
    Wen, Shaoyan
    Zhang, Bin
    Cao, Xuchen
    Wang, Xin
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 131 (02) : 483 - 490
  • [3] Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer
    Yunwei Han
    Zhihao Yu
    Shaoyan Wen
    Bin Zhang
    Xuchen Cao
    Xin Wang
    Breast Cancer Research and Treatment, 2012, 131 : 483 - 490
  • [4] Incidence of Chemotherapy-Induced Ovarian Failure in Premenopausal Women Undergoing Chemotherapy for Breast Cancer
    V. Tiong
    A. M. Rozita
    N. A. Taib
    C. H. Yip
    C. H. Ng
    World Journal of Surgery, 2014, 38 : 2288 - 2296
  • [5] The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients
    Vriens, Ingeborg J. H.
    De Bie, Ashley J. R.
    Aarts, Maureen J. B.
    de Boer, Maaike
    van Hellemond, Irene E. G.
    Roijen, Joyce H. E.
    van Golde, Ron J. T.
    Voogd, Adri C.
    Tjan-Heijnen, Vivianne C. G.
    ONCOTARGET, 2017, 8 (07) : 11372 - 11379
  • [6] Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials
    Furlanetto, Jenny
    Marme, Frederik
    Seiler, Sabine
    Thode, Christian
    Untch, Michael
    Schmatloch, Sabine
    Schneeweiss, Andreas
    Bassy, Martina
    Fasching, Peter A.
    Strik, Dominika
    Stickeler, Elmar
    Schem, Christian
    Karn, Thomas
    Grischke, Eva-Maria
    Denkert, Carsten
    van Mackelenbergh, Marion
    Mueller, Volkmar
    Nekljudova, Valentina
    Loibl, Sibylle
    EUROPEAN JOURNAL OF CANCER, 2021, 152 : 193 - 203
  • [7] Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer
    Lambertini, Matteo
    Del Mastro, Lucia
    Viglietti, Giulia
    Ponde, Noam F.
    Solinas, Cinzia
    de Azambuja, Evandro
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (01)
  • [8] Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer
    Matteo Lambertini
    Lucia Del Mastro
    Giulia Viglietti
    Noam F. Pondé
    Cinzia Solinas
    Evandro de Azambuja
    Current Treatment Options in Oncology, 2017, 18
  • [9] Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure
    van Hellemond, Irene E. G.
    Vriens, Ingeborg J. H.
    Peer, Petronella G. M.
    Swinkels, Astrid C. P.
    Smorenburg, Carolien H.
    Seynaeve, Caroline M.
    van der Sangen, Maurice J. C.
    Kroep, Judith R.
    de Graaf, Hiltje
    Honkoop, Aafke H.
    Erdkamp, Frans L. G.
    van den Berkmortel, Franchette W. Pj
    de Boer, Maaike
    de Roos, Wilfred K.
    Linn, Sabine C.
    Imholz, Alexander L. T.
    Tjan-Heijnen, Vivianne C. G.
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (01) : 274 - 283
  • [10] Oxidative stress and chemotherapy-induced ovarian ablation in premenopausal women with breast cancer
    Belwalkar, G. J.
    Kulkarni, Aruna
    Joshi, R.
    BIOMEDICAL RESEARCH-INDIA, 2010, 21 (01): : 63 - 66